Do current approaches to assessing therapy related adverse events align with the needs of long-term cancer patients and survivors?
Syril D PettitRebecca KirchPublished in: Cardio-oncology (London, England) (2018)
The increasing efficacy of cancer therapeutics means that the timespan of cancer therapy administration is undergoing a transition to increasingly long-term settings. Unfortunately, chronic therapy-related adverse health events are an unintended, but not infrequent, outcome of these life-saving therapies. Historically, the cardio-oncology field has evolved as retrospective effort to understand the scope, mechanisms, and impact of treatment-related toxicities that were already impacting patients. This review explores whether current systemic approaches to detecting, reporting, tracking, and communicating AEs are better positioned to provide more proactive or concurrent information to mitigate the impact of AE's on patient health and quality of life. Because the existing tools and frameworks for capturing these effects are not specific to cardiology, this study looks broadly at the landscape of approaches and assumptions. This review finds evidence of increasing focus on the provision of actionable information to support long-term health and quality of life for survivors and those on chronic therapy. However, the current means to assess and support the impact of this burden on patients and the healthcare system are often of limited relevance for an increasingly long-lived survivor and patient population.
Keyphrases
- end stage renal disease
- public health
- healthcare
- health information
- ejection fraction
- mental health
- cancer therapy
- peritoneal dialysis
- squamous cell carcinoma
- mesenchymal stem cells
- drug delivery
- cross sectional
- papillary thyroid
- acute kidney injury
- social media
- bone marrow
- single cell
- patient reported outcomes
- risk assessment
- lymph node metastasis
- childhood cancer